

Sarah Danson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4116137/publications.pdf>

Version: 2024-02-01

40
papers

735
citations

567281

15
h-index

552781

26
g-index

41
all docs

41
docs citations

41
times ranked

1243
citing authors

#	ARTICLE	IF	CITATIONS
1	Senescence and Cancer: A Review of Clinical Implications of Senescence and Senotherapies. <i>Cancers</i> , 2020, 12, 2134.	3.7	134
2	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1511-1521.	1.1	95
3	IAPs as a Target for Anticancer Therapy. <i>Current Cancer Drug Targets</i> , 2007, 7, 785-794.	1.6	66
4	Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer. <i>Oncolmmunology</i> , 2019, 8, e1593810.	4.6	44
5	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 233.	1.6	41
6	Economic burden of resected (stage IB-IIIa) non-small cell lung cancer in France, Germany and the United Kingdom: A retrospective observational study (LuCaBIS). <i>Lung Cancer</i> , 2018, 124, 298-309.	2.0	34
7	A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1647-1656.	1.1	34
8	Adjuvant treatment patterns and outcomes in patients with stage IB-IIIa non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. <i>Lung Cancer</i> , 2018, 124, 310-316.	2.0	27
9	Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1. <i>Annals of Oncology</i> , 2011, 22, 1653-1660.	1.2	26
10	Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms. <i>Lancet</i> , The, 2015, 385, S98.	13.7	26
11	A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3094-3094.	1.6	25
12	Sunitinib versus dacarbazine as first-line treatment in patients with metastatic uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9031-9031.	1.6	19
13	An exploratory randomized-controlled trial of the efficacy of the Src-kinase inhibitor saracatinib as a novel analgesic for cancer-induced bone pain. <i>Journal of Bone Oncology</i> , 2019, 19, 100261.	2.4	16
14	Macrophages Mediate the Antitumor Effects of the Oncolytic Virus HSV1716 in Mammary Tumors. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 589-601.	4.1	16
15	Olaparib as maintenance treatment in patients with chemosensitive small cell lung cancer (STOMP): A randomised, double-blind, placebo-controlled phase II trial. <i>Lung Cancer</i> , 2022, 171, 26-33.	2.0	16
16	Are we over-treating with checkpoint inhibitors?. <i>British Journal of Cancer</i> , 2019, 121, 629-630.	6.4	15
17	Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE). <i>Clinical Cancer Research</i> , 2021, 27, 1882-1892.	7.0	15
18	High-Resolution Array CGH Analysis Identifies Regional Deletions and Amplifications of Chromosome 8 in Uveal Melanoma. , 2015, 56, 3460.		13

#	ARTICLE	IF	CITATIONS
19	The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma. BMC Cancer, 2021, 21, 761.	2.6	12
20	Genome-Wide Analysis of Circulating Cell-Free DNA Copy Number Detects Active Melanoma and Predicts Survival. Clinical Chemistry, 2018, 64, 1338-1346.	3.2	9
21	Ganetespib in Combination with Pemetrexedâ€“Platinum Chemotherapy in Patients with Pleural Mesothelioma (MESO-02): A Phase Ib Trial. Clinical Cancer Research, 2020, 26, 4748-4755.	7.0	9
22	The Acute Oncologist's Role in Managing Patients with Cancer and other Comorbidities. Journal of Comorbidity, 2012, 2, 10-17.	3.9	6
23	DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244); Tj ETQq1 1 0.784314 rgBT /Ov 1.6	1.6	6
24	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Final results for the AVAST-M trial.. Journal of Clinical Oncology, 2017, 35, 9501-9501.	1.6	6
25	Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: Preplanned interim results for the AVAST-M trial.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	5
26	A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer.. Journal of Clinical Oncology, 2020, 38, e21649-e21649.	1.6	5
27	Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC â€“ The ETOP/EORTC SPLENDOUR and AMGEN-249 trials. Lung Cancer, 2021, 161, 76-85.	2.0	4
28	Ipilimumab in the real world: The U.K. expanded access programme (EAP) experience in advanced melanoma.. Journal of Clinical Oncology, 2013, 31, 3018-3018.	1.6	4
29	Response to guadecitabine (SGI-110) combined with cisplatin and gemcitabine (GCC) in platinum refractory germ cell tumors (GCTs).. Journal of Clinical Oncology, 2020, 38, e17057-e17057.	1.6	3
30	Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy. Molecular and Clinical Oncology, 2020, 13, 73.	1.0	2
31	Phase II study of bortezomib with cisplatin as first-line treatment of malignant pleural mesothelioma (MPM): EORTC 08052.. Journal of Clinical Oncology, 2012, 30, 7081-7081.	1.6	1
32	A randomized phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma.. Journal of Clinical Oncology, 2012, 30, TPS8605-TPS8605.	1.6	1
33	Implications and benefits of the NICE appraisal of pembrolizumab. British Journal of Health Care Management, 2015, 21, 506-508.	0.2	0
34	DNA methyltransferase inhibitor guadecitabine combined with cisplatin and gemcitabine chemotherapy (SPIRE): Randomized expansion phase as neoadjuvant therapy for bladder urothelial carcinoma.. Journal of Clinical Oncology, 2021, 39, 447-447.	1.6	0
35	Implications of smoking for quality of life and illness perceptions of lung cancer patients.. Journal of Clinical Oncology, 2012, 30, 6113-6113.	1.6	0
36	AVAST-M: Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence.. Journal of Clinical Oncology, 2013, 31, LBA9000-LBA9000.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Deciphering antitumour response and resistance with intratumour heterogeneity (DARWIN II).. Journal of Clinical Oncology, 2017, 35, TPS9099-TPS9099.	1.6	0
38	SPIRE: A phase Ib/randomised IIa open label clinical trial combining guadecitabine (SGI-110) with cisplatin and gemcitabine chemotherapy for solid malignancies including bladder cancer.. Journal of Clinical Oncology, 2018, 36, TPS4594-TPS4594.	1.6	0
39	CONFIRM: A phase III randomized trial to evaluate the efficacy of nivolumab versus placebo in relapsed mesothelioma.. Journal of Clinical Oncology, 2018, 36, TPS8586-TPS8586.	1.6	0
40	Effect of carboplatin when administered after dacarbazine failure: Clinical benefit of sequential therapy. Molecular and Clinical Oncology, 2020, 13, 1-1.	1.0	0